Studi del 2012 riguardanti il CRM197:
Studi del 2011 riguardanti il CRM197 :
Studi del 2010 riguardanti il CRM197 :
Studi del 2009 riguardanti il CRM197 :
( studio italiano dell'Università di Camerino )
1.P Libby. The pathogenesis of atherosclerosis. Harrison’s Principles of Internal Medicine. E Braunwald, A Fauci, DL Kasper, SL Hauser, DL Longo, IL Jameson Editors. McGraw-Hill, 15th Edition, pp 1377-1378, 2001.
2.R Ross. Atherosclerosis-an inflammatory disease (review). N Engl J Med 340: 119-126, 1999.
3.GK Hansson, X Zhou, E Törnquist, et al. The role of adaptive immunity in atherosclerosis. Ann N Y Acad Sci, 902: 53-64. 2000.
4.S Blotnick, GE Peoples, MR Freeman, et al. T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: Differential production and release by CD4+ and CD8+ T cells. Proc Ntl Acad Sci USA 91: 2890-2894, 1994.
5.FB Boudi, CH Ahsan, JL Orford, et al. Atherosclerosis. eMedicine, from WebMD pp 1-19 (last updated August 17, 2006).
6.S Ellison. The hidden origin of statin drugs. News with Views.com April 2005.
7.J Armitage. The safety of statins in clinical practice.Lancet 370: 1781-1790, 2007.
8.FDA statement (for immediate release), December 3, 2006.
9.Merck/Schering Plough Pharmaceutica provides results of the ENHANCE trial. January 14, 2008.
10.JJ Kastelein, F Akdim, ES Stroes, et al. Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia. N Engl J Med 358: 1431- 1443, 2008.
11.AB RossebØ, TR Pedersen, K Boman, et al. Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis. N Engl J Med 359: 1343-1356.
12.GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised,double-blind , placebo controlled trial. Lancet 372: 1331-1339, 2008.
13.S de Ferranti, DS Ludwig. Storm over Statins- The Controversy Surrounding Pharmacologic Treatment of Children. N Engl J Med 359: 1309-1312, 2008.
14. L Barksdale, L Garmise, K Horibata. Virulence, toxinogeny, and lisogeny in Corynebacterium diphtheriae. Ann NY Acad Sci 88: 1093-1108, 1960.
15.R Rappuoli. New and Improved Vaccines Against Diphtheria and Tetanus. In GC Woodrow, MM Levine. New Generation Vaccines, 251-268. M DekkerInc. New York and Basel, 1990.
16.Diphtheria toxin Safety Data Sheet. Division of Safety National Institute of Health, p 5
17.T Uchida, AM Pappenheimer Jr, R Greany. Diphtheria toxin and related proteins Isolation and properties of mutant proteins serologically related to diphtheria toxin. J Biol Chem 248, 3838-3844, 1973.
18.P Anderson. Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the non-toxic protein CRM197. Infect Immun 39: 233-238. 1983.
19.P Anderson, ME Pichichero, RA Insel. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197. J Clin Invest 76: 52-59, 1985.
20.M Peltola, T Kilpi, M Anttila. Rapid disappearance of Haemophilus influenzae tipe b meningitis after routine childhood immunization with conjugated vaccines. Lancet 340: 592-594, 1992.
21.E L Anderson, T Bowers, C M Mink, et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 3391-3395, 1994.
22.M B Rennels, K M Edwards, H L Keyserling, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics, 101: 604-611, 1998.
23.H R Shinefield, S Black, P Ray, et al. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugated vaccine in infants and toddlers. Pediatr Infect Dis J, 18: 757-763, 1999.
24.S Black, H Shinefield, B Fireman, et al. Efficacy, safety, immunogenicity of heptavalent pneumococcal conjugate vaccine in children. The America Journal of Managed Care 6: 536-549, 2000.
25.MB Rennels, KM Edwards, HL Keyserling, et al. Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine coniugated to CRM197 in United States infants. Pediatr Infect Dis J 20: 153-159.
26.G Eskola, T Kilpi, A Palmu, et al. Efficacy of a pneumococcal conjugate vaccine, against acute otitis media. N Engl J Med, 344: 403409, 2001.
27.KP Klugman, SA Madhi, RE Huebner, et al. A trial of a 9-valent pneumococcal conjugated vaccine in children with and those without HVI infection. N Engl J Med, 349: 1341-1348, 2003.
28.AM Pappenheimer Jr, T Uchida, AA Harper. An immunological study of the diphtheria toxin molecule. Immunochemestry , 9: 891-906, 1972.
29.S Buzzi, I Maistrello. Inhibition of Growth of Ehrlich Tumors in Swiss Mice by Diphtheria Toxin. Cancer Res, 33: 2349-2353, 1973.
30.S Buzzi, L Buzzi. Cancer Immunity after Treatment of Ehrlich Tumor with Diphtheria Toxin. Cancer Res,34: 3481-3486, 1974.
31.S Buzzi. Diphtheria Toxin in Cancer Therapy. Lancet, I: 628-629, 1974.
32.S Buzzi. Diphtheria Toxin Treatment of Human Advanced Cancer. Cancer Res, 42: 2054-2058, 1982.
33.G Cukor, M Solotorovsky, RJ Kuchler.. Biological Activity of Heated Diphtheria Toxin. J Bacteriol,115: 277-283,1973.
34.S Buzzi, G Buzzi, AM Buzzi. Diphtheria toxoid immunotherapy of human advanced cancer. 85th annual meeting of AACR, San Francisco, 1994.
35.S Buzzi, C Baccini, D Rubboli, et al. Immunological effects of a boiled diphtheria toxoid on high risk cancer patients. 88th annual meeting of AACR, San Diego,1997.
36.S Buzzi, G Buzzi, AM, Buzzi, et al. CRM197: effects in cancer patients. 89th annual meeting AACR, New Orleans, 1998.
37.S Buzzi, C Baccini, D Rubboli, et al. Phase I-II study of CRM197 administration to 50 advanced cancer patients. AACR-NCI-EORTC international conference, Washington, 1999.
38.S Buzzi, C Baccini, D Rubboli, et al. Antitumor effects of CRM197: preferential activity in lymph nodes. 91st annual meeting AACR, San Francisco, 2000.
39.S Buzzi, D Rubboli, C Baccini, et al. Cancer immunotherapy with CRM197, a nontoxic mutant of diphtheria toxin. Proc 6th world congress on advances in oncology. Crete (Greece) 2001.
40.S Buzzi, D Rubboli, G Buzzi, et al. CRM197: phagocyte mediated antitumor activity followed by a connective proliferation tending to encapsulate the tumor. 93rd annual meeting AACR, San Francisco, 2002.
41.S Buzzi, D Rubboli, G Buzzi, et al. CRM197 antitumor activity. Possible mechanism of action. 94th annual meeting AACR, Toronto, 2003.
42.S Buzzi, D Rubboli, G Buzzi, et al. CRM197: effects of intravenous administration to advanced cancer patients. 95th annual meeting AACR, Orlando, 2004.
43.S Buzzi, D Rubboli, G Buzzi, et al. CRM197 (nontoxic diphtheria toxin): effects on advanced cancer patients. Cancer Immunol Immunother 53: 1041-1048, 2004.
44.S Buzzi, D Rubboli, G Buzzi, et al. CRM197 and cancer: effects of intratumoral administration. Therapy 1: 61-66, 2004.
45.G Raab, M Klagsbrun. Heparin binding EGF-like growth factor. Biochim Biophys Acta 1333: 179-199 (2) 1997.
46.S Higashiyama, JA Abraham, J Miller, et al. A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991.
47.JG Naglich, JE Metherall, DW Hassal, et al. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF.like growth factor precursor. Cell 69: 1051-1061, 1992.
48.S Higashiyama, JA Abraham, M Klagsbrun. Heparin-bindig EGF-like growth factor stimulation of smooth muscle cells migration: dependence on interactions with cell surface heparan sulphate. ICB 122: 933-940, 1993.
49.K Elenius, S Paul, G Allison, et al. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. Embo J 16: 1268-1278, 1997.
50.PP Ongusaha, JC KwaK, AJ Zwible. HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64: 5283-5290, 2004.
51.S Matsumoto, K Kishida, I Shimomura, et al. Increased plasma HB-EGF associated with obesity and coronary artery disease. Biochem Biophys Res Comm 292: 781-786, 2002 .
52.J Miyagawa, S Higashiyama, S Kawata, et al. Localization of heparin-binding EGF-like growth factor in the smooth muscle cells and macrophages of human atherosclerotic plaques. J Clin Invest, 95: 404-411, 1995.
53.A Nakata, JI Miyagawa, S Yamasita, et al. Localization of Heparin-binding epidermal growth factor-like growth factor in human coronary arteries. Circulation 94: 2778-2786, 1996.
54.TJ Reape, VJ Wilson, JM Kanczler, et al. Detection and Cellular localization of Heparin-Binding Epidermal Growth Factor- like Growth Factor mRNA and Protein in Human Atherosclerotic Tissue. J Mol and Cel Cardiol, 29 (6): 1639-1648 (10), 1997.
55.M Kaefer, S Vemulapalli, ML Freeman. A nontoxic diphtheria toxin analogue inhibits neonatal bladder smooth muscle cells proliferation. J Urol 163: 580-584, 2000.
56.S Miyamoto, N Hirata, A Yomazaki, et al. Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727, 2004.
57.T Mitamura, S Higashiyama, N Taniguchi, et al. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. J Biol Chem 270: 1015-1019, 1995.
58.GS Bixler jr, R Eby, KM Dermody, et al.Synthetic peptide representing a T-cell epitope of CRM197 as carrier molecule in a Hemophilus influenzae tipe b conjugate vaccine. Adv Exp Med Biol 251: 175-180, 1989.
59.AK Abbas , AH Lichtman, JS Pober. Immunologia cellulare e molecolare, 274-281, 1994.
60.S Buzzi, G Buzzi, AM Buzzi, et al. CRM197: reduction of atherosclerotic stenoses in carotids of three elderly patients. Therapy, 4:293-298, 2007.
61.S Chaturvedi, A Bruno, T Feasby, et al. Carotid endarterectomy —An evidence-based review: Report of the therapeutics and technology. Assessment Subcommittee of the American Academy of Neurology. Neurology, 65: 794-799, 2005.
62.SPREAD, Stroke Prevention and Educational Awareness Diffusion, V edizione. Ictus cerebrale: Linee guida italiane di prevenzione e trattamento. 350-356, 2007.
63.G Bartolozzi, R Rappuoli. I vaccini. Gli effetti collaterali, le precauzioni e le controindicazioni. Pagg. 32-37, UTET, 2001.
64.Common Terminology Criteria for Adverse Events (CTCAE). Publish date: August 2006.
65.JM Rolf, L Eidels. Structure-function analyses of Diphtheria Toxin by use of monoclonal antibodies. Infect Immun 61 (3): 994-1003, 1993.
66.C Yuan, KW Beach, LH Smith Jr, et al. Measurement of atherosclerotic carotid plaque size in vivo using high resolution magnetic resonance imaging. Circulation 24: 2666- 2671, 1998.
67.R Corti, V Fuster, ZA Fayad, et al. Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions. A prospective, randomized, double blind trial with high-resolution magnetic resonance imaging. JACC 46: 106-112, 2005.